{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:14:33Z","timestamp":1780600473765,"version":"3.54.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Opinion statement<\/jats:title><jats:p>The therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process. While this appears promising, autologous CAR-Ts are limited due to the lack of accessibility, manufacturing delays, and variable product quality. To overcome these, allogeneic (allo) CARs from healthy donors appear appealing. These can be immediately available as \u201coff the shelf\u201d ready-to-use products of standardized and superior quality exempt from the effects of an immunosuppressive tumor microenvironment and prior treatments, and potentially with lower healthcare utilization using industrialized scale production. Allogeneic CARs, however, are not devoid of complications and require genomic editing, especially with \u03b1\u03b2 T cells to avoid graft versus host disease (GvHD) and allo-rejection by the recipient\u2019s immune system. Tools for genomic editing such as TALEN and CRISPR provide promise to develop truly \u201coff the shelf\u201d universal CARs and further advance the field of cellular immunotherapy. Several allogeneic CARs are currently in early phase clinical trials, and preliminary data is encouraging. Longer follow-up is required to truly assess the feasibility and safety of these techniques in the patients. This review focuses on the strategies for developing allogeneic CARs along with cell sources and clinical experience thus far in lymphoma.<\/jats:p>","DOI":"10.1007\/s11864-021-00920-6","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T07:02:42Z","timestamp":1645772562000},"page":"171-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0949","authenticated-orcid":false,"given":"Arushi","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"920_CR1","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"920_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"\u2022 Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphomA. N Engl J Med. 2017;377:2531\u201344 First landmark registration trial for the CAR-T product axicabtagene ciloleucel that resulted in its approval for relapsed\/refractory aggressive non-Hodgkin lymphoma.","journal-title":"N Engl J Med"},{"key":"920_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"\u2022 Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354 Landmark registration trial for the CAR-T product tisagenlecleucel that resulted in its approval for relapsed\/refractory aggressive non-Hodgkin lymphoma.","journal-title":"N Engl J Med"},{"key":"920_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"\u2022 Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352 Landmark registration trial for the CAR-T product lisocabtagene maraleucel that resulted in its approval for relapsed\/refractory aggressive non-Hodgkin lymphoma.","journal-title":"Lancet"},{"key":"920_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol."},{"key":"920_CR6","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"\u2022 Nastoupil LJ, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328 First real-world evidence of use of axicabtagene ciloleucel including patients who would not have been eligible for ZUMA-1 clinical trial.","journal-title":"J Clin Oncol"},{"key":"920_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood. 2019;134:764.","journal-title":"Blood"},{"key":"920_CR8","doi-asserted-by":"crossref","unstructured":"Riedell PA, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Blood. 2019;134:\u20131599.","DOI":"10.1182\/blood-2019-127490"},{"key":"920_CR9","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38:3095\u2013106.","journal-title":"J Clin Oncol"},{"key":"920_CR10","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL). J Clin Oncol. 2020;38:8008.","journal-title":"J Clin Oncol"},{"key":"920_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"\u2022 Wang M, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342 Landmark registration trial for the CAR-T product brexucabtagene autoleucel that resulted in its approval for relapsed\/refractory Mantle Cell lymphoma.","journal-title":"N Engl J Med"},{"key":"920_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"920_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"920_CR14","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4:2871\u201383.","journal-title":"Blood Adv"},{"key":"920_CR15","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:4898\u2013911.","journal-title":"Blood Adv"},{"key":"920_CR16","doi-asserted-by":"crossref","unstructured":"Khurana A et al. Lines of therapy before autologous stem cell transplant (ASCT) and CAR-T infusion affect outcomes in aggressive non-Hodgkin\u2019s lymphoma (NHL). 2021.","DOI":"10.1016\/S2666-6367(21)00074-9"},{"key":"920_CR17","doi-asserted-by":"publisher","unstructured":"Tully S et al. Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model. JCO Clin Cancer Inform 2019;1\u20139. https:\/\/doi.org\/10.1200\/cci.19.00086.","DOI":"10.1200\/cci.19.00086"},{"key":"920_CR18","first-page":"206","volume":"26","author":"A Khurana","year":"2020","unstructured":"Khurana A, Ansell SM. Role of microenvironment in non-hodgkin lymphoma: understanding the composition and biology. Cancer Journal (United States). 2020;26:206\u201316.","journal-title":"Cancer Journal (United States)"},{"key":"920_CR19","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","volume":"25","author":"M Byrne","year":"2019","unstructured":"Byrne M, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. Biology of Blood and Marrow Transplantation. 2019;25:e344\u201351.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"920_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nature Reviews Drug Discovery. 2020;19:185\u201399.","journal-title":"Nature Reviews Drug Discovery"},{"key":"920_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs. 2017;31:473\u201381.","journal-title":"BioDrugs"},{"key":"920_CR22","doi-asserted-by":"crossref","unstructured":"Butler CL, Valenzuela NM, Thomas KA, Reed EF. Not all antibodies are created equal: factors that influence antibody mediated rejection. J Immunol Res 2017;2017.","DOI":"10.1155\/2017\/7903471"},{"key":"920_CR23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. 2018;53:521\u201334.","journal-title":"Bone Marrow Transplantation"},{"key":"920_CR24","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease\u2014biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167\u201379.","journal-title":"N Engl J Med"},{"key":"920_CR25","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u201379.","journal-title":"N Engl J Med"},{"issue":"3","key":"920_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/biomedicines5030035","volume":"5","author":"H Abdelhakim","year":"2017","unstructured":"Abdelhakim H, Abdel-Azim H, Saad A. Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease. Biomedicines. 2017;5(3):35.","journal-title":"Biomedicines"},{"key":"920_CR27","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood.V99.5.1572","volume":"99","author":"JJ Van Rood","year":"2002","unstructured":"Van Rood JJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99:1572\u20137.","journal-title":"Blood"},{"key":"920_CR28","doi-asserted-by":"crossref","unstructured":"R\u00e5destad E et al. Individualization of hematopoietic stem cell transplantation using alpha\/beta T-cell depletion. Front Immunol 2019;10.","DOI":"10.3389\/fimmu.2019.00189"},{"key":"920_CR29","doi-asserted-by":"crossref","unstructured":"R\u00e5destad E et al. Alpha\/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors. J Immunol Res 2014;2014.","DOI":"10.1155\/2014\/578741"},{"key":"920_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112\u201321.","journal-title":"J Clin Oncol"},{"key":"920_CR31","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129\u201339.","journal-title":"Blood"},{"key":"920_CR32","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1182\/blood.V122.21.2956.2956","volume":"122","author":"CRY Cruz","year":"2013","unstructured":"Cruz CRY, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2956\u201373.","journal-title":"Blood"},{"key":"920_CR33","doi-asserted-by":"publisher","unstructured":"Bishop DC, et al. Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2021010813.","DOI":"10.1182\/blood.2021010813"},{"key":"920_CR34","doi-asserted-by":"publisher","unstructured":"Micklethwaite KP, et al. Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2021010858.","DOI":"10.1182\/blood.2021010858"},{"key":"920_CR35","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113\u201323.","journal-title":"Blood"},{"key":"920_CR36","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","volume":"114","author":"PJ Hanley","year":"2009","unstructured":"Hanley PJ, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958\u201367.","journal-title":"Blood"},{"key":"920_CR37","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","volume":"116","author":"JJ Melenhorst","year":"2010","unstructured":"Melenhorst JJ, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700\u20132.","journal-title":"Blood"},{"key":"920_CR38","unstructured":"Long term outcomes of tabelecleucel (allogeneic third-party.... EHA Library. Prockop S. Jun 15 2018; 214869. https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/214869\/susan.prockop.long.term.outcomes.of.tabelecleucel.28allogeneic.third-party.html?f=listing%3D4%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D664306."},{"key":"920_CR39","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","volume":"51","author":"RJ O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections. Bone Marrow Transplantation. 2016;51:1163\u201372.","journal-title":"Bone Marrow Transplantation"},{"key":"920_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733\u201347.","journal-title":"J Clin Invest"},{"key":"920_CR41","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins HS, et al. Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells. Blood. 2009;114:4099\u2013107.","journal-title":"Blood"},{"key":"920_CR42","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1182\/blood-2003-12-4431","volume":"104","author":"AE Foster","year":"2004","unstructured":"Foster AE, et al. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood. 2004;104:2403\u20139.","journal-title":"Blood"},{"key":"920_CR43","doi-asserted-by":"crossref","unstructured":"Turtle CJ et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8.","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"920_CR44","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/leu.2014.174","volume":"29","author":"WK Chan","year":"2015","unstructured":"Chan WK, et al. Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia. 2015;29:387\u201395.","journal-title":"Leukemia"},{"key":"920_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger C, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294\u2013305.","journal-title":"J Clin Invest"},{"key":"920_CR46","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med"},{"key":"920_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior anti-tumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"},{"key":"920_CR48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","volume":"2017","author":"K Tarte","year":"2017","unstructured":"Tarte K. Role of the microenvironment across histological subtypes of NHL. Hematology. 2017;2017:610\u20137.","journal-title":"Hematology"},{"key":"920_CR49","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.14694\/EdBook_AM.2013.33.e91","volume":"33","author":"SM Ansell","year":"2013","unstructured":"Ansell SM, Vonderheide RH. Cellular composition of the tumor microenvironment. Am Soc Clin Oncol Educ B. 2013;33:e91\u20137.","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"920_CR50","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750\u20139.","journal-title":"Blood"},{"key":"920_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"920_CR52","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall AL, et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019;3:2812\u20135.","journal-title":"Blood Adv"},{"key":"920_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40259-021-00473-y","volume":"35","author":"C Manriquez-Roman","year":"2021","unstructured":"Manriquez-Roman C, Siegler EL, Kenderian SS. CRISPR takes the front seat in CART-cell development. BioDrugs. 2021;35:113\u201324.","journal-title":"BioDrugs"},{"key":"920_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd.2016.280","volume":"16","author":"H Yin","year":"2017","unstructured":"Yin H, Kauffman KJ, Anderson DG. Delivery technologies for genome editing. Nature Reviews Drug Discovery. 2017;16:387\u201399.","journal-title":"Nature Reviews Drug Discovery"},{"key":"920_CR55","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"\u2022 Torikai H, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697\u2013705 This is the first study describing the development of allogeneic universal CAR T cells using gene editing by eliminating TCR as a way to avoid GvHD.","journal-title":"Blood"},{"key":"920_CR56","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"LPB Philip","year":"2015","unstructured":"Philip LPB, et al. Multiplex genome-edited T-cell manufacturing platform for \u2018off-the-shelf\u2019 adoptive T-cell immunotherapies. Cancer Res. 2015;75:3853\u201364.","journal-title":"Cancer Res"},{"key":"920_CR57","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255\u201366.","journal-title":"Clin Cancer Res"},{"key":"920_CR58","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","volume":"8","author":"J Ren","year":"2017","unstructured":"Ren J, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002\u201311.","journal-title":"Oncotarget"},{"key":"920_CR59","doi-asserted-by":"crossref","unstructured":"Qasim W et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 2017;9.","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"920_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"920_CR61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"\u2022 Eyquem J, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137 This study shows the advantages of targeting the CAR directly to the TRAC locus.","journal-title":"Nature"},{"key":"920_CR62","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod DT, et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol. Ther. 2017;25:949\u201361.","journal-title":"Mol. Ther."},{"key":"920_CR63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omtm.2016.12.008","volume":"4","author":"M Hale","year":"2017","unstructured":"Hale M, et al. Homology-directed recombination for enhanced engineering of chimeric antigen receptor T cells. Mol Ther Methods Clin Dev. 2017;4:192\u2013203.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"920_CR64","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis C, et al. Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T cells mediate potent anti-leukemic effects. Mol Ther. 2018;26:1215\u201327.","journal-title":"Mol Ther"},{"key":"920_CR65","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396:1885\u201394.","journal-title":"Lancet"},{"key":"920_CR66","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, et al. Toward eliminating HLA class i expression to generate universal cells from allogeneic donors. Blood. 2013;122:1341\u20139.","journal-title":"Blood"},{"key":"920_CR67","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya Y, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy. Cancer Immunol Res. 2020;8:926\u201336.","journal-title":"Cancer Immunol Res"},{"key":"920_CR68","doi-asserted-by":"crossref","unstructured":"Lee J et al. Abrogation of HLA surface expression using CRISPR\/Cas9 genome editing: a step toward universal T cell therapy. Sci Rep 2020;10.","DOI":"10.1038\/s41598-020-74772-9"},{"key":"920_CR69","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse GG, et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol. 2017;35:765\u201372.","journal-title":"Nat Biotechnol"},{"key":"920_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.stem.2012.07.014","volume":"11","author":"CJ Taylor","year":"2012","unstructured":"Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient hla types. Cell Stem Cell. 2012;11:147\u201352.","journal-title":"Cell Stem Cell"},{"key":"920_CR71","doi-asserted-by":"crossref","unstructured":"Han J et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 2015;5.","DOI":"10.1038\/srep11483"},{"key":"920_CR72","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo anti-tumor activity against human multiple myeloma. Leukemia. 2014;28:917\u201327.","journal-title":"Leukemia"},{"key":"920_CR73","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.exphem.2005.07.006","volume":"33","author":"H Guven","year":"2005","unstructured":"Guven H, et al. Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol. 2005;33:1320\u20138.","journal-title":"Exp Hematol"},{"key":"920_CR74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","volume":"17","author":"H Klingemann","year":"2015","unstructured":"Klingemann H. Challenges of cancer therapy with natural killer cells. Cytotherapy. 2015;17:245\u20139.","journal-title":"Cytotherapy"},{"key":"920_CR75","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563\u201370.","journal-title":"Cytotherapy"},{"key":"920_CR76","first-page":"652","volume":"8","author":"JH Gong","year":"1994","unstructured":"Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8:652\u20138.","journal-title":"Leukemia"},{"key":"920_CR77","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","volume":"57","author":"T M\u00fcller","year":"2008","unstructured":"M\u00fcller T, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008;57:411\u201323.","journal-title":"Cancer Immunol Immunother"},{"key":"920_CR78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Frontiers in Immunology. 2018;9:283.","journal-title":"Frontiers in Immunology"},{"key":"920_CR79","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity. Leukemia. 2018;32:520\u201331.","journal-title":"Leukemia"},{"key":"920_CR80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"\u2022 Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353 A seminal paper showing feasibility in a phase I clinical trial of umbilical cord blood-derived CAR-NK cells in B cell malignancies.","journal-title":"N Engl J Med"},{"key":"920_CR81","doi-asserted-by":"crossref","unstructured":"Shah N et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8.","DOI":"10.1371\/journal.pone.0076781"},{"key":"920_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23:181\u201392.e5.","journal-title":"Cell Stem Cell"},{"key":"920_CR83","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2019-130584","volume":"134","author":"C Chang","year":"2019","unstructured":"Chang C, et al. FT819: translation of off-the-shelf TCR-Less Trac-1XX CAR-T cells in support of first-of-kind phase I clinical trial. Blood. 2019;134:4434.","journal-title":"Blood"},{"key":"920_CR84","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1046\/j.1365-2567.2000.00001.x","volume":"100","author":"M Exley","year":"2000","unstructured":"Exley M, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 2000;100:37\u201347.","journal-title":"Immunology"},{"key":"920_CR85","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/archderm.135.5.546","volume":"135","author":"BJ Nickoloff","year":"1999","unstructured":"Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol. 1999;135:546\u201352.","journal-title":"Arch Dermatol"},{"key":"920_CR86","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","volume":"119","author":"A Chaidos","year":"2012","unstructured":"Chaidos A, et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:5030\u20136.","journal-title":"Blood"},{"key":"920_CR87","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood-2010-08-303008","volume":"117","author":"DB Leveson-Gower","year":"2011","unstructured":"Leveson-Gower DB, et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011;117:3220\u20139.","journal-title":"Blood"},{"key":"920_CR88","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","volume":"124","author":"D Schneidawind","year":"2014","unstructured":"Schneidawind D, et al. CD41 invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD41CD251FoxP31 regulatory T cells. Blood. 2014;124:3320\u20138.","journal-title":"Blood"},{"key":"920_CR89","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo A, et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell. 2018;34:596\u2013610.e11.","journal-title":"Cancer Cell"},{"key":"920_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/cmi.2012.44","volume":"10","author":"S Kalyan","year":"2013","unstructured":"Kalyan S, Kabelitz D. Defining the nature of human \u03b3\u03b4 T cells: a biographical sketch of the highly empathetic. Cellular and Molecular Immunology. 2013;10:21\u20139.","journal-title":"Cellular and Molecular Immunology"},{"key":"920_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-06-3069","volume":"67","author":"D Kabelitz","year":"2007","unstructured":"Kabelitz D, Wesch D, He W. Perspectives of \u03b3\u03b4 T cells in tumor immunology. Cancer Research. 2007;67:5\u20138.","journal-title":"Cancer Research"},{"key":"920_CR92","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938\u201345.","journal-title":"Nat Med"},{"key":"920_CR93","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos B, Serre K, Norell H. \u03b3\u03b4T cells in cancer. Nature Reviews Immunology. 2015;15:683\u201391.","journal-title":"Nature Reviews Immunology"},{"key":"920_CR94","doi-asserted-by":"crossref","unstructured":"Cutmore LC, Marshall JF. Current perspectives on the use of off the shelf car-t\/nk cells for the treatment of cancer. Cancers 2021;13.","DOI":"10.3390\/cancers13081926"},{"key":"920_CR95","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","volume":"11","author":"M Rozenbaum","year":"2020","unstructured":"Rozenbaum M, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.","journal-title":"Front Immunol"},{"key":"920_CR96","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","volume":"38","author":"SS Neelapu","year":"2020","unstructured":"\u2022 Neelapu SS, et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study. J Clin Oncol. 2020;38:8002 Preliminary data for the feasibility and activity of the first allogeneic CAR-T product in lymphoma.","journal-title":"J Clin Oncol"},{"key":"920_CR97","doi-asserted-by":"crossref","unstructured":"First allogeneic CAR T-cell therapy impresses in relapsed\/refractory lymphoma. Oncologist 2020;25:S4.","DOI":"10.1634\/theoncologist.2020-0570"},{"key":"920_CR98","doi-asserted-by":"publisher","unstructured":"First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed\/refractory large B-cell lymphoma (R\/R LBCL): ALPHA2 study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2529.","DOI":"10.1200\/JCO.2021.39.15_suppl.2529"},{"key":"920_CR99","doi-asserted-by":"publisher","unstructured":"Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed\/refractory (r\/r) CD19+ NHL. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7516.","DOI":"10.1200\/JCO.2021.39.15_suppl.7516"},{"key":"920_CR100","doi-asserted-by":"publisher","unstructured":"A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9\u2013engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (CARBON). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS7570.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7570"},{"key":"920_CR101","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1200\/JCO.2021.39.15_suppl.7548","volume":"39","author":"JC Chavez","year":"2021","unstructured":"Chavez JC, et al. Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5. J Clin Oncol. 2021;39:7548.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00920-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00920-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00920-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T05:17:48Z","timestamp":1666675068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00920-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00920-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"12 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arushi Khurana declares that she has no conflict of interest. Yi Lin has received research funding (paid to Mayo Clinic) from Kite\/Gilead, Celgene\/Bristol-Myers Squibb, bluebird bio, Janssen, Legend Biotech, Takeda, Merck, and Boston Scientific; has served as a consultant for Kite\/Gilead, Celgene\/Bristol-Myers Squibb, Juno\/Bristol-Myers Squibb, Janssen, Legend Biotech, Gamida Cell Ltd, Novartis, Iovance Biotherapeutics, Takeda, and Fosun Kite Biotechnology Co., Ltd; and has served on a Data Safety Monitoring Board (DSMB) for Sorrento Therapeutics. All funds were paid directly to Mayo Clinic. Dr. Lin received no personal compensation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}